MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Abbott Laboratories

Suletud

SektorTervishoid

131.61 -0.75

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

131.07

Max

132.62

Põhinäitajad

By Trading Economics

Sissetulek

7.6B

9.2B

Müük

339M

11B

P/E

Sektori keskmine

17.363

63.778

Aktsiakasum

1.34

Dividenditootlus

1.78

Kasumimarginaal

84.099

Töötajad

114,000

EBITDA

82M

3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+6.47% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.78%

2.39%

Järgmine tulemuste avaldamine

16. apr 2025

Järgmine dividendimakse kuupäev

15. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

15. apr 2025

Turustatistika

By TradingEconomics

Turukapital

7.8B

230B

Eelmine avamishind

132.36

Eelmine sulgemishind

131.61

Uudiste sentiment

By Acuity

27%

73%

75 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Abbott Laboratories Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2025, 19:03 UTC

Tulu

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22. jaan 2025, 18:20 UTC

Tulu

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22. jaan 2025, 12:45 UTC

Tulu

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

1. nov 2024, 14:15 UTC

Suurimad hinnamuutused turgudel

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

1. nov 2024, 10:10 UTC

Suurimad hinnamuutused turgudel

Reckitt Shares Surge After Baby Formula Lawsuit Win

31. okt 2024, 23:57 UTC

Kuumad aktsiad

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31. okt 2024, 23:14 UTC

Suurimad hinnamuutused turgudel

Abbott Laboratories Shares Rise After Baby-Formula Verdict

16. okt 2024, 12:03 UTC

Tulu

Abbott Laboratories 3Q Sales Top Expectations

1. veebr 2025, 18:14 UTC

Peamised uudised

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22. jaan 2025, 16:40 UTC

Peamised uudised
Tulu

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22. jaan 2025, 15:20 UTC

Tulu

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22. jaan 2025, 15:08 UTC

Tulu

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. jaan 2025, 13:51 UTC

Tulu

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22. jaan 2025, 13:39 UTC

Peamised uudised
Tulu

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. jaan 2025, 12:02 UTC

Tulu

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22. jaan 2025, 12:01 UTC

Tulu

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22. jaan 2025, 12:01 UTC

Tulu

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q Net $9.23B >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q Sales $10.97B >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q EPS $5.27 >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q Adj EPS $1.34 >ABT

22. jaan 2025, 09:54 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

1. nov 2024, 17:33 UTC

Market Talk

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

16. okt 2024, 14:21 UTC

Peamised uudised
Tulu

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

16. okt 2024, 12:25 UTC

Tulu

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

16. okt 2024, 12:02 UTC

Peamised uudised
Tulu

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

16. okt 2024, 11:59 UTC

Tulu

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

16. okt 2024, 11:37 UTC

Tulu

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

6.47% tõus

12 kuu keskmine prognoos

Keskmine 140.21 USD  6.47%

Kõrge 158 USD

Madal 117 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

14

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

126.3 / 133.46Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

75 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.